Replies to post #611327 on ORIONS Money Stocks

[TheFinalCD]

TPST TRYING FOR 7 BREAK & HOLD

[Golden Cross]

$PCSA $6.9 Million cash and cash equivalents: At September 30, 2023, we had cash and cash equivalents totaling $6.9 million. Based on our current plans, we believe our current cash balances will enable us to complete our current clinical trial in NGC-Capecitabine (NGC-Cap, also known as PCS6422), prepare for a Phase 2 trial for NGC-Cap, and fund our administrative costs through the second quarter of 2024.